Systems-level, multiomic approaches are now used across a broad range of clinical studies, with a growing impact in areas such as cancer therapy. Pharma is also increasingly recognizing the value of proteogenomics in particular for more efficient drug development, where it is opening up new possibilities for robust drug target identification, for example. After years of outstanding success with our Olink® Target 96 offering of multiplex protein biomarker panels with qPCR readout, 2020 saw the launch of the Olink® Explore platform, offering high-throughput proteomics with readout on the Illumina® NovaSeq 6000 and NextSeq NGS systems.
At this virtual meeting, you will learn more about Olink Explore and how it can be integrated into your facility, enabling you to offer high throughput multiomics, which customers are increasingly demanding. You will hear keynote presentations by leading researchers and get a unique opportunity for exclusive insights into the latest developments in Olink's game-changing protein biomarker discovery by our Olink experts. Representatives from Illumina will also share information on their NovaSeq 6000/NextSeq NGS platform and how this can be incorporated into large-scale multiomics studies.
Agenda Overview Below:
Associate Director · Biogen
Arnav Mehta, M.D., Ph.D.
Postdoctoral Associate, Hacohen and Lander labs
Broad Institute of MIT and Harvard